Skip to content

Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial

Exocarpium Citri Grandis Relieves Symptoms of Novel Coronavirus Pneunomia (COVID-19): a Randomized Controlled Clinical Trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000030804
Enrollment
Unknown
Registered
2020-03-15
Start date
2020-02-01
Completion date
Unknown
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Sponsors

Maoming People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1) aged between 18 and 75 years old; (2) Common type patients with confirmed COVID-19 according to the diagnostic criteria of "novel coronavirus Infection Diagnosis and Treatment Plan (Trial 6th Edition)" issued by the National Health and Safety Commission; (3) Patients and their families voluntarily participated in the study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Female patients during pregnancy or lactation; (2) Patients with allergy to Exocarpium Citri Grandis preparation, patients with intolerance to the recommended dose of Exocarpium Citri Grandis were previously applied; (3) Patients who are taking part in clinical trials of other drugs; (4) Patients are taking other foods or drugs with antitussive and antiasthmatic effects. (5) There are other serious diseases that may threaten life, such as cancer.

Design outcomes

Primary

MeasureTime frame
Cough Score;Expectoration score;

Secondary

MeasureTime frame
Hospital Stay;Inflammatory Factor Level;

Countries

China

Contacts

Public ContactHu Linhui

Maoming People's Hospital

hulinhui@live.cn+86 13580013426

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026